Association of LncRNA HMlincRNA717 with prognosis in pancreatic cancer.

Objective: The aim of this study was to investigate the expression of LncRNA HMlincRNA717 in human pancreatic cancer and its correlation with clinicopathological features

Patients And Methods: Using reverse transcription quantitative polymerase chain reaction, HMlincRNA717 expression was detected in primary pancreatic cancer tissues. The correlation of HMlincRNA717 with clinicopathological features and prognosis were also analyzed. Survival analysis was performed using the Kaplan-Meier method and Cox's proportional hazards model.

Results: The expression of HMlincRNA717 was significantly decreased in pancreatic cancer tissues compared with paired adjacent normal tissues (p < 0.01). It was also proved that HMlincRNA717 expression was to be associated with clinical stage (p = 0.001), tumor size (p < 0.001), lymph node metastasis (p = 0.003), and distant metastasis (p < 0.001) in pancreatic cancer patients. Significantly shorter 5-year overall survival (OS) were observed in patients with lower expression of the HMlincRNA717 (p < 0.01). Multivariate analysis showed that decreased HMlincRNA717 expression was a poor independent prognostic factor for pancreatic cancer patients.

Conclusions: Our findings showed that the expression of lncRNA HMlincRNA717 was down-regulated in pancreatic cancer and associated with overall survival, suggesting that HMlincRNA717 could be a potential prognostic biomarker for pancreatic cancer progression.